Renovaro Inc. (RENB) - Operatsion marja

Renovaro Biosciences (RENB) kompaniyasining korporativ logotipi

Renovaro Inc. (RENB) startap muhitida intiluvchan ma'lumotlar olimlari va immunoterapiya ekspertlarini birlashtiradi. GURU.Markets tizimi grafigidagi asosiy operatsiyalarning rentabelligi hujayra terapiyasi va genom tahrirlash bo'yicha ma'lumotlarni o'z ichiga olgan bo'lib, bunda 0.00 yakuniy daraja belgisi vazifasini bajaradi. Biroq, onkologiyadagi sun'iy intellektning erta bosqichdagi ishlanmalariga eksklyuziv e'tibor biofarmatsevtika sektori uchun xos bo'lgan yuqori binar risklarni yuzaga keltiradi.

Enochian BioSciences (RENB): Operatsion foyda normasi 21.02.2024dan 01.10.2025gacha

Renovaro Biosciences - tahliliy kesimlar va asosiy koʻrsatkichlar (RENB)

- bozor kapitallashuvi ko'rsatkichlari:
Kompaniyaning dastlabki tahlili:RENB, Enochian BioSciences
Renovaro brendining mahsuloti

Shaxsiylashtirilgan hujayra terapiyasi va AI vaksinalarini ishlab chiqayotgan Renovaro Inc. uchun tadqiqot va ishlanmalar (R&D) xarajatlaridan tijorat daromadlariga o'tish asosiy omil bo'ladi. Tarixiy operatsion marja umumiy aylanmadan foizlar va soliqlar to'lovigacha bo'lgan operatsion foyda ulushini aks ettiradi, bu esa investorlarga resurslarni boshqarish samaradorligini va biznesning texnologik ishlanmalarni haqiqiy daromadga aylantirish qobiliyatini baholash imkonini beradi.

Raqobatdosh kompaniyalar

Operatsion rentabellik BeiGene Ltd|Halozyme Therapeutics - Operatsion foyda marjasi|Sotuvning operatsion marjasi RVMD (Revolution Medicines Corp)|Operatsion foyda koeffitsiyenti AAPG|Operatsion rentabellik CG Oncology Therapeutics CGON|Operatsion foyda normasi URGN|BCAX: Sotuvning operatsion marjasi|PSNL: Operatsion rentabellik|Erasca (ERAS) - Operatsion rentabellik|DCTH - Operatsion faoliyat rentabelligi|YMAB (Y-mAbs Corp) - Operatsion marja|Sotuvning operatsion marjasi Aura Biosciences (AURA)|Operatsion rentabellik Candel Therapeutics Inc. (CADL)|Sotuvning operatsion marjasi Accuray, Inc. ARAY|Operatsion rentabellik sellaslifesciences.com SLS|Operatsion foyda normasi ACTU|CTOR - Operatsion rentabellik|Operatsion faoliyat rentabelligi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operatsion rentabellik|FATE: Operatsion foyda koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Operatsion marja|TCRX (TScan Therapeutics) - Operatsion foyda koeffitsiyenti|Operatsion rentabellik Champions Oncology (CSBR)|Operatsion faoliyat rentabelligi XBiotech USA|Operatsion rentabellik CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Sotuvning operatsion rentabelligi|RADX - Operatsion rentabellik|ARTV - Operatsion marja|Adlai Nortye Ltd (ANL) - Operatsion rentabellik|Veru Pharma - Operatsion foyda normasi|Operatsion rentabellik Tempest Therapeutics Corp|Operatsion foyda bo'yicha sotuv rentabelligi XLO (Xilio Therapeutics, Inc.)|Operatsion rentabellik Mural Oncology PLC (MURA)|Operatsion marja Kairos Pharma (KAPA)|Operatsion rentabellik onkuretherapeutics.com OKUR|GDTC: Operatsion foyda bo'yicha sotuv rentabelligi|CRIS: Sotuvning operatsion marjasi|apollomicsinc.com (APLM) - Sotuvning operatsion marjasi|THAR: Operatsion marja|Sotuvning operatsion marjasi Advanced Biomed Inc.|Sotuvning operatsion marjasi GNPX|Operatsion foyda bo'yicha sotuv rentabelligi CLDI (Calidi Biotherapeutics)|Operatsion marja SBFM|Xenetic Biosciences, Inc. - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion rentabellik Salarius Pharmaceuticals SLRX|Operatsion marja purple-biotech.com PPBT|AONC - Operatsion rentabellik|BGNE: Operatsion rentabellik|CKPT: Operatsion marja|Elevation Oncology - Operatsion foyda normasi|ICAD (iCAD) - Operatsion marja|IKNA: Operatsion foyda normasi|Operatsion rentabellik Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operatsion foyda normasi|Operatsion rentabellik MorphoSys Corporation MOR|NAYA: Operatsion foyda bo'yicha sotuv rentabelligi|Ascentage Pharma Group International - Operatsion marja